The Somewhat Positive Press Coverage Extremely Likely to Affect BioDelivery Sciences International (BDSI) Stock Price

The Somewhat Positive Press Coverage Extremely Likely to Affect BioDelivery Sciences International (BDSI) Stock Price

Here are some of the news headlines that may have impacted Alpha One Sentiment Analysis’s rankings:

Press coverage about BioDelivery Sciences International (NASDAQ:BDSI) has been trending somewhat positive recently, AlphaOne Sentiment reports. The research group, a service of Accern, scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioDelivery Sciences International earned a media sentiment score of 0.13 on AlphaOne’s scale. AlphaOne also gave news headlines about the specialty pharmaceutical company an impact score of 100 out of 100, meaning that recent media coverage is extremely likely to have an impact on the company’s share price in the next several days.

BioDelivery Sciences International (BDSI) opened at 2.35 on Monday. The company’s market capitalization is $130.01 million. BioDelivery Sciences International has a one year low of $1.50 and a one year high of $3.10. The firm has a 50-day moving average of $1.96 and a 200-day moving average of $1.90. BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Monday, May 15th. The specialty pharmaceutical company reported $0.58 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.49. The firm had revenue of $29.48 million during the quarter, compared to the consensus estimate of $27.07 million. BioDelivery Sciences International had a negative return on equity of 309.49% and a negative net margin of 93.61%. On average, analysts anticipate that BioDelivery Sciences International will post $0.22 earnings per share for the current year.

In related news, CEO Mark A. Sirgo sold 110,895 shares of the stock in a transaction dated Friday, March 31st. The stock was sold at an average price of $1.90, for a total value of $210,700.50. Following the completion of the transaction, the chief executive officer now owns 1,670,157 shares of the company’s stock, valued at $3,173,298.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 112,345 shares of company stock valued at $213,456 in the last three months. 9.00% of the stock is currently owned by company insiders. About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:BDSI”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment